Biodefence Market Scope And Analysis

Report Code : TIPRE00005377
Category : Biotechnology

No. of Pages : 150

Buy Now

Biodefense Market Scope and Analysis by 2031

Buy Now

Biodefense Market Report Scope

Report Attribute	Details
Market size in 2021	US$ 12.37 Billion
Market Size by 2031	US$ 21.62 Billion
Global CAGR (2023 - 2031)	6.1%
Historical Data	2021-2023
Forecast period	2024-2031
Segments Covered	By Product Anthrax Smallpox Botulism Radiation Nuclear
Regions and Countries Covered	North America US Canada Mexico Europe UK Germany France Russia Italy Rest of Europe Asia-Pacific China India Japan Australia Rest of Asia-Pacific South and Central America Brazil Argentina Rest of South and Central America Middle East and Africa South Africa Saudi Arabia UAE Rest of Middle East and Africa
Market leaders and key company profiles	Bavarian Nordic Alnylam Pharmaceuticals Inc SIGA Technologies Emergent BioSolutions Inc Cleveland Bio Labs Dynavax Technologies Elusys Therapeutics Inc Soligenix Altimmune Pluristem

Biodefense Market News and Recent Developments

The biodefense market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. The following is a list of developments in the market for biodefense and strategies:

In February 2022, Appili Therapeutics Inc. announced funding of over US$ 10 million from the US Department of Defense, via the Joint Science and Technology Office of the Defense Threat Reduction Agency, to advance the company’s biodefense vaccine candidate, ATI-1701, a potential first-in-class vaccine candidate to prevent infection with Francisella tularensis. The funding is expected to boost the company's presence and increase growth in the biodefense market. (Source: Appili Therapeutics, Press Release, 2022)
In September 2022, Emergent BioSolutions Inc. completed its definitive agreement with Chimerix, Inc. to acquire Chimerix's exclusive global rights to TEMBEXA (brincidofovir), the first oral antiviral approved by the US Food and Drug Administration (FDA) for the treatment of smallpox in all age groups. (Source: Emergent BioSolutions Inc., News Release, 2022)
In July 2023, Emergent BioSolutions Inc. received approval from the US FDA for CYFENDUS (Anthrax Vaccine Adsorbed, Adjuvanted), previously known as AV7909, for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis in individuals 18 to 65 years of age when administered in conjunction with recommended antibacterial drugs. (Source: Emergent BioSolutions Inc., News Release, 2023)

Biodefense Market Report Coverage and Deliverables

The “Biodefense Market Size and Forecast (2021–2031)” report provides a detailed analysis of the market covering below areas:

Market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
Market dynamics such as drivers, restraints, and key opportunities
Key future trends
Detailed PEST/Porter’s Five Forces and SWOT analysis
Global and regional market analysis covering key market trends, major players, regulations, and recent market developments
Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments
Detailed company profiles